Novavax

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Novavax 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NVAX

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. 

CEO
John C.s Jacobs
CEOJohn C.s Jacobs
Employees
952
Employees952
Headquarters
Gaithersburg, Maryland
HeadquartersGaithersburg, Maryland
Founded
1987
Founded1987
Employees
952
Employees952

NVAX Key Statistics

Market cap
1.08B
Market cap1.08B
Price-Earnings ratio
3.77
Price-Earnings ratio3.77
Dividend yield
Dividend yield
Average volume
3.74M
Average volume3.74M
High today
$6.87
High today$6.87
Low today
$6.64
Low today$6.64
Open price
$6.67
Open price$6.67
Volume
6.92M
Volume6.92M
52 Week high
$11.55
52 Week high$11.55
52 Week low
$5.01
52 Week low$5.01

Stock Snapshot

With a market cap of 1.08B, Novavax(NVAX) trades at $6.69. The stock has a price-to-earnings ratio of 3.77.

During the trading session on 2025-12-20, Novavax(NVAX) shares reached a daily high of $6.87 and a low of $6.64. At a current price of $6.69, the stock is +0.8% higher than the low and still -2.5% under the high.

Trading volume for Novavax(NVAX) stock has reached 6.92M, versus its average volume of 3.74M.

The stock's 52-week range extends from a low of $5.01 to a high of $11.55.

The stock's 52-week range extends from a low of $5.01 to a high of $11.55.

NVAX News

Nasdaq 2d
Interesting NVAX Call Options For February 2026

Investors in Novavax, Inc. (Symbol: NVAX) saw new options become available this week, for the February 2026 expiration. At Stock Options Channel , our YieldBoos...

Interesting NVAX Call Options For February 2026
Simply Wall St 7d
Novavax Valuation Check as FDA Scrutiny Rises and Activist Pushes for Possible Sale

Novavax (NVAX) is back in the spotlight after a controversial FDA memo signaled tougher vaccine approval standards, just as an activist shareholder ramps up pre...

Novavax Valuation Check as FDA Scrutiny Rises and Activist Pushes for Possible Sale

Analyst ratings

50%

of 10 ratings
Buy
50%
Hold
20%
Sell
30%

People also own

Based on the portfolios of people who own NVAX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.